2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
-
- Michael Heuser
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
-
- Sylvie D. Freeman
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;
-
- Gert J. Ossenkoppele
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
-
- Francesco Buccisano
- Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
-
- Christopher S. Hourigan
- Laboratory of Myeloid Malignancy, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD;
-
- Lok Lam Ngai
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
-
- Jesse M. Tettero
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
-
- Costa Bachas
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
-
- Constance Baer
- MLL Munich Leukemia Laboratory, Munich, Germany;
-
- Marie-Christine Béné
- Department of Hematology and Biology, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;
-
- Veit Bücklein
- Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany;
-
- Anna Czyz
- Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland;
-
- Barbara Denys
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University;
-
- Richard Dillon
- Department of Medical and Molecular Genetics, King’s College, London, United Kingdom;
-
- Michaela Feuring-Buske
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
-
- Monica L. Guzman
- Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;
-
- Torsten Haferlach
- MLL Munich Leukemia Laboratory, Munich, Germany;
-
- Lina Han
- Department of Leukemia and
-
- Julia K. Herzig
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
-
- Jeffrey L. Jorgensen
- The Department of Hematopathology, MD Anderson Cancer Center, Houston, TX;
-
- Wolfgang Kern
- MLL Munich Leukemia Laboratory, Munich, Germany;
-
- Marina Y. Konopleva
- Department of Leukemia and
-
- Francis Lacombe
- Hematology Biology, Flow Cytometry, Bordeaux University Hospital, Pessac, France;
-
- Marta Libura
- Medical University of Warsaw, Warsaw, Poland;
-
- Agata Majchrzak
- Department of Experimental Hematology, Copernicus Memorial Hospital, Lodz, Poland;
-
- Luca Maurillo
- Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
-
- Yishai Ofran
- Department of Hematology, Shaare Zedek Medical Center Faculty of Medicine Hebrew University, Jerusalem Israel;
-
- Jan Philippe
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University;
-
- Adriana Plesa
- Department of Hematology Laboratory, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France;
-
- Claude Preudhomme
- Laboratory of Hematology, CHU Université de Lille, Lille, France;
-
- Farhad Ravandi
- Department of Leukemia and
-
- Christophe Roumier
- Laboratory of Hematology, CHU Université de Lille, Lille, France;
-
- Marion Subklewe
- Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany;
-
- Felicitas Thol
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
-
- Arjan A. van de Loosdrecht
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
-
- Bert A. van der Reijden
- Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands;
-
- Adriano Venditti
- Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
-
- Agnieszka Wierzbowska
- Department of Hematology, Medical University of Lodz, Lodz, Poland;
-
- Peter J. M. Valk
- Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands;
-
- Brent L. Wood
- Department of Hematopathology, Children's Hospital Los Angeles, CA;
-
- Roland B. Walter
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Christian Thiede
- Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany; and
-
- Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
-
- Gail J. Roboz
- Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;
-
- Jacqueline Cloos
- Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
抄録
<jats:title>Abstract</jats:title><jats:p>Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.</jats:p>
収録刊行物
-
- Blood
-
Blood 138 (26), 2753-2767, 2021-12-30
American Society of Hematology